Input 2021.01.13 08:24
“The South African mutant virus is one of our concerns,” said Dave Riggs (CEO) of the US pharmaceutical company Eli Lilly, on the 12th (local time). Revealed.
Anthony Pouch, director of the National Institute of Allergy and Infectious Diseases (NIAID), the nation’s leading infectious disease expert, expressed a similar view. Pouch said at the’Schmidt Future Forum’ event on the day that the South African mutant virus could pose a threat to antibody treatments, he said, “I am uneasy.”
According to preliminary data, the South African mutant virus could evade some of the protective functions provided by antibody treatments, “a more threat,” said Pouch. “It may affect the protective function of a single antibody therapy and perhaps a vaccine,” he said. “It’s a problem that I take very seriously.”
On the other hand, unlike antibody treatments, vaccines or antiviral treatments can be effective against mutant viruses, the developers argue. Ugur Sahin, CEO of Bioentech, Germany, who developed the vaccine with Pfizer, and Daniel Oday, CEO of Gilead Sciences, who created the antiviral drug remdesivir, recently appeared on the air and announced that the company’s products can also prevent mutated viruses.
According to the Centers for Disease Control and Prevention (CDC), the South African mutant virus has not yet been found in the United States. At least 72 cases of the UK mutant virus have been reported.